AMED 📈 Amedisys - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0234361089

AMED: Home Care, Hospice Care, Rehabilitation Services, Nursing Services

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Web URL: https://www.amedisys.com

Additional Sources for AMED Stock

AMED Stock Overview

Market Cap in USD 2,994m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Services
IPO / Inception 1994-08-17

AMED Stock Ratings

Growth 5y -53.8%
Fundamental 39.5%
Dividend -
Rel. Strength Industry -316
Analysts 2.9/5
Fair Price Momentum 71.35 USD
Fair Price DCF 160.95 USD

AMED Dividends

No Dividends Paid

AMED Growth Ratios

Growth Correlation 3m -83.5%
Growth Correlation 12m 9.4%
Growth Correlation 5y -80%
CAGR 5y -12.17%
CAGR/Mean DD 5y -0.26
Sharpe Ratio 12m -1.26
Alpha -28.92
Beta 0.60
Volatility 26.06%
Current Volume 2375k
Average Volume 20d 664.6k
What is the price of AMED stocks?
As of December 22, 2024, the stock is trading at USD 84.47 with a total of 2,375,039 shares traded.
Over the past week, the price has changed by -1.41%, over one month by -6.14%, over three months by -13.19% and over the past year by -11.11%.
Is Amedisys a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Amedisys (NASDAQ:AMED) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 39.45 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMED as of December 2024 is 71.35. This means that AMED is currently overvalued and has a potential downside of -15.53%.
Is AMED a buy, sell or hold?
Amedisys has received a consensus analysts rating of 2.90. Therefor, it is recommend to hold AMED.
  • Strong Buy: 0
  • Buy: 1
  • Hold: 8
  • Sell: 0
  • Strong Sell: 1
What are the forecast for AMED stock price target?
According to ValueRays Forecast Model, AMED Amedisys will be worth about 77.7 in December 2025. The stock is currently trading at 84.47. This means that the stock has a potential downside of -7.99%.
Issuer Forecast Upside
Wallstreet Target Price 96.3 14%
Analysts Target Price 96.1 13.8%
ValueRay Target Price 77.7 -8%